MONECO Advisors LLC boosted its holdings in Stryker Co. (NYSE:SYK – Get Rating) by 4.5% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,235 shares of the medical technology company’s stock after acquiring an additional 53 shares during the period. MONECO Advisors LLC’s holdings in Stryker were worth $330,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Claremont Financial Group Inc. bought a new stake in shares of Stryker during the first quarter valued at approximately $25,000. Cassady Schiller Wealth Management LLC bought a new stake in shares of Stryker during the fourth quarter valued at approximately $27,000. Retirement Group LLC raised its holdings in shares of Stryker by 86.8% during the fourth quarter. Retirement Group LLC now owns 99 shares of the medical technology company’s stock valued at $27,000 after buying an additional 46 shares during the last quarter. Exane Derivatives bought a new stake in shares of Stryker during the first quarter valued at approximately $27,000. Finally, Princeton Global Asset Management LLC raised its holdings in shares of Stryker by 1,212.5% during the first quarter. Princeton Global Asset Management LLC now owns 105 shares of the medical technology company’s stock valued at $28,000 after buying an additional 97 shares during the last quarter. Institutional investors own 74.52% of the company’s stock.
Stryker Trading Up 0.7 %
Stryker stock opened at $215.79 on Friday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.15 and a current ratio of 2.00. The firm has a market cap of $81.60 billion, a price-to-earnings ratio of 39.74, a price-to-earnings-growth ratio of 2.60 and a beta of 1.03. Stryker Co. has a 1 year low of $188.84 and a 1 year high of $281.16. The firm’s 50 day moving average price is $207.39 and its two-hundred day moving average price is $237.24.
Stryker Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 31st. Shareholders of record on Friday, September 30th will be given a dividend of $0.695 per share. This represents a $2.78 annualized dividend and a yield of 1.29%. The ex-dividend date is Thursday, September 29th. Stryker’s payout ratio is 51.20%.
Analysts Set New Price Targets
A number of research firms have recently weighed in on SYK. Robert W. Baird cut their price target on Stryker from $297.00 to $240.00 and set an “outperform” rating on the stock in a report on Wednesday, July 27th. Morgan Stanley cut their price target on Stryker from $270.00 to $220.00 and set an “equal weight” rating on the stock in a report on Friday, July 15th. Bank of America lowered shares of Stryker from a “buy” rating to a “neutral” rating in a research note on Monday, July 11th. Deutsche Bank Aktiengesellschaft lowered shares of Stryker from a “buy” rating to a “hold” rating and lowered their price objective for the company from $285.00 to $205.00 in a research note on Thursday, July 21st. Finally, Piper Sandler lowered their price objective on shares of Stryker from $290.00 to $250.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 27th. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average price target of $256.00.
About Stryker
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies.
Read More
- Get a free copy of the StockNews.com research report on Stryker (SYK)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.